Related references
Note: Only part of the references are listed.The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Janis M. Taube et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy
Wei Chang Colin Tan et al.
CANCER COMMUNICATIONS (2020)
Association between low estrogen receptor positive breast cancer and staining performance
Dennis Caruana et al.
NPJ BREAST CANCER (2020)
Digital pathology and artificial intelligence
Muhammad Khalid Khan Niazi et al.
LANCET ONCOLOGY (2019)
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
Sonja Althammer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Breelyn A. Wilky
IMMUNOLOGICAL REVIEWS (2019)
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
Steve Lu et al.
JAMA ONCOLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
S. N. Gettinger et al.
NATURE COMMUNICATIONS (2018)
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Nicolas A. Giraldo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3-LBA: immunogenicity, biomarkers and PK assays)
Shalini Gupta et al.
BIOANALYSIS (2017)
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
Edwin R. Parra et al.
SCIENTIFIC REPORTS (2017)
Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial
John W. Peabody et al.
BMC UROLOGY (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Janice M. Mehnert et al.
CLINICAL CANCER RESEARCH (2017)
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips
So-Woon Kim et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2016)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis
Edward C. Stack et al.
METHODS (2014)
Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues
Anna Sapino et al.
FRONTIERS IN ONCOLOGY (2013)
Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis
A McCabe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Share Paper
